Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

OptiMedica (Sunnyvale, CA), a commercial-stage medical device company focused on laser technology for cataract surgery, closed a $35M Series E financing. Participants include Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners and Bio*One Capital.

TriReme Medical (Pleasanton, CA), a commercial-stage medical device company focused on percutaneous devices for the treatment of coronary and peripheral arterial disease, closed an $18M Series E financing. Participants include Luminor Capital.

TransMedics (Andover, MA) a commercial-stage medical device company focused on organ preservation technologies for transplants, closed a $36M Series E financing. Participants include Abrams Capital, Flagship Ventures, Hercules Technology Growth Capital and Kleiner Perkins Caufield & Byers.

EarlySense (Israel), a commercial-stage HealthIT company offering a fully integrated patient monitoring and supervision platform, closed a $15M Series E financing. Participants include Pitango Venture Capital, JK&B Captial, ProSeed VC Fund, Docor International Management and Bridge Investment Fund. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds […]

Ambit Biosciences (San Diego, CA), a clinical-stage biotechnology company focused on kinase-based therapeutics for cancer, closed a $25M Series E financing. Participants include OrbiMed Advisors, Aisling Capital, Apposite Healthcare, Roche Ventures, GrowthWorks, MedImmune Ventures, Forward Ventures, GIMV, and Radius Ventures. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate […]

Quantia Communications (Waltham, MA), a HealthIT company and maker of an online physician community and collaboration platform, has closed a $12M Series E. Participants include Fuse Capital. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Dfine (San Jose, CA) a commercial-stage medical device company focused on minimally invasive therapeutic devices used to treat pathologies of the vertebrae, closed a $25 million Series E financing. Participants include OrbiMed, Prospect Venture Partners, Split Rock Partners, BBT Capital, Highland Capital Management and Vanguard Ventures.

C8 MediSensors (San Jose, CA) a clinical-stage medical device company focused on non-invasive continuous glucose monitors, closed a $24M Series E financing. Participants have included GE Healthymagination Fund.

Aviir (Irvine, CA) a commercial-stage diagnostic company focused on pharmacogenomic and genetic tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders, closed a $10M Series E financing. Participants include Merck Global Health Innovation, Bay City Capital, Aberdare Ventures and New Leaf Venture Partners.

Portola Pharmaceuticals (South San Francisco, CA) a clinical-stage small moelcule company focused on acute and chronic cardiovascular and autoimmune and inflammatory diseases, closed an $89M Series E financing. Participants included Temasek, Eastern Capital Limited, D.E. Shaw, Adage Capital Management, BBT Capital Management, Janus Capital Group and Pac-Link BioVentures.

Edison Pharmaceuticals (Mountain View, CA) a clinical-stage small molecule company focused on mitochondrial disease Friedreich’s ataxia, closed a $4.1M Series E financing. Participants were not identified. Thanx for your patience as we catch-up.

CardioKinetix (Redwood City, CA) a clinical-stage medical device company focused on transcatheter implants for congestive heart failure, closed a $44M Series E financing. Participants include SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners, J.P. Morgan Partners, H&Q Healthcare Investors and H&Q Life Sciences Investors.

Revance Therapeutics (Newark, CA) a clinical-stage biopharmaceutical company developing botulinum toxin type A products focused on topical indications such as lateral canthal lines and hyperhidrosis, closed a $45M Series E financing. Participants include Essex Woodlands Health Ventures, NovaQuest Capital, CNF Investments, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital […]

« Previous Entries  Next Page »

to top of page...